Contrast-induced nephropathy (CIN) is defined as the impairment of renal function—measured as either a 25% increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44 µmol/L) increase in absolute SCr value—within 48-72 hours after intravenous contrast administration. Contrast-Induced Nephropathy (CIN): Current State of the Evidence on Contrast Media and Prevention of CIN However, reviews of evidence should not be construed to represent clinical recommendations or guidelines. Suarez-Cuervo C, Zhang A, Sherrod C, Aboagye J, Eng J, Choi MJ, Hutfless S Prevention of Contrast Induced Nephropathy (CIN) Guidelines This procedural document supersedes: PAT/T 48 v.1 - Guidelines for Prevention Katzberg R W Contrast Induced Nephropathy in 2010. Journal of Applied Radiology (Sept 2010) vol 39, No 9 CONTRAST-INDUCED NEPHROPATHY PREVENTION -TYPES OF CONTRAST AGENT o ACC/AHA guidelines on percutaneous coronary intervention were revised to suggest the use of either an (Visipaque 320) Dimer 290 Iso. PREVENTION -INTRAVENOUS SALINE Contrast-induced nephropathy (CIN) is a widely recognized and clinically significant problem in patients undergoing an increasing number of minimally invasive procedures that require contrast administration. Study shows GE Healthcare's Visipaque TM Associated with Lower Incidence of Contrast-Induced Nephropathy and contrast media (CM) iodixanol (Visipaque) guidelines recommend the use of Contrast-induced nephropathy (CIN) is defined as the impairment of renal function and is measured as either a 25% increase in serum creatinine (SCr) from baseline or 0.5 mg/dL (44 µmol/L) increase in absolute value, within 48-72 hours of intravenous contrast administration. Key Words: Visipaque iodixanol low-osmolar contrast media contrast-induced nephropathy C ontrast-induced nephropathy (CIN) is associated with significant morbidity and mortality,1-3 thus, multiple strategies to adjust modifiable risk factors associated with CIN have been explore